Jefferies Financial Group Raises DexCom (DXCM) Price Target to $148.00

DexCom (NASDAQ:DXCM) had its price objective boosted by Jefferies Financial Group to $148.00 in a research note published on Wednesday, The Fly reports. The firm currently has a buy rating on the medical device company’s stock. Jefferies Financial Group also issued estimates for DexCom’s Q4 2018 earnings at $0.17 EPS, FY2018 earnings at ($0.09) EPS, Q1 2019 earnings at $0.00 EPS, Q2 2019 earnings at $0.19 EPS, Q3 2019 earnings at $0.00 EPS, Q4 2019 earnings at $0.21 EPS, FY2019 earnings at $0.40 EPS and FY2020 earnings at $0.30 EPS.

Other equities analysts have also recently issued reports about the stock. Stephens reiterated a buy rating and set a $135.00 price objective on shares of DexCom in a research report on Thursday, August 2nd. Bank of America upped their price objective on shares of DexCom from $106.00 to $127.00 and gave the stock a buy rating in a research report on Thursday, August 2nd. Canaccord Genuity upped their price objective on shares of DexCom from $105.00 to $125.00 and gave the stock a buy rating in a research report on Thursday, August 2nd. Oppenheimer set a $125.00 price objective on shares of DexCom and gave the stock a buy rating in a research report on Thursday, August 2nd. Finally, BidaskClub cut shares of DexCom from a strong-buy rating to a buy rating in a research report on Tuesday, July 31st. Seven research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. DexCom has a consensus rating of Buy and a consensus price target of $132.50.

DXCM stock traded up $1.05 during trading on Wednesday, reaching $149.46. 1,594,508 shares of the company were exchanged, compared to its average volume of 1,254,658. The stock has a market cap of $12.85 billion, a price-to-earnings ratio of -257.69 and a beta of 0.60. DexCom has a twelve month low of $49.80 and a twelve month high of $152.14. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.71 and a quick ratio of 4.62.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Tuesday, November 6th. The medical device company reported $0.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.29. The business had revenue of $266.70 million during the quarter, compared to analysts’ expectations of $242.72 million. DexCom had a net margin of 4.72% and a negative return on equity of 2.89%. DexCom’s quarterly revenue was up 44.5% on a year-over-year basis. On average, equities research analysts anticipate that DexCom will post -0.22 EPS for the current fiscal year.

In other news, EVP Andrew K. Balo sold 5,000 shares of the stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $124.25, for a total transaction of $621,250.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 11,161 shares of the stock in a transaction on Monday, August 13th. The stock was sold at an average price of $123.22, for a total transaction of $1,375,258.42. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 157,892 shares of company stock valued at $21,864,030. Corporate insiders own 1.80% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of DXCM. Dimensional Fund Advisors LP increased its position in shares of DexCom by 16.7% during the first quarter. Dimensional Fund Advisors LP now owns 148,342 shares of the medical device company’s stock worth $11,001,000 after buying an additional 21,271 shares during the period. Principal Financial Group Inc. increased its position in shares of DexCom by 7.9% during the first quarter. Principal Financial Group Inc. now owns 33,469 shares of the medical device company’s stock worth $2,482,000 after buying an additional 2,459 shares during the period. UBS Group AG increased its position in shares of DexCom by 76.3% during the first quarter. UBS Group AG now owns 15,926 shares of the medical device company’s stock worth $1,181,000 after buying an additional 6,890 shares during the period. Clinton Group Inc. acquired a new stake in shares of DexCom during the second quarter worth $201,000. Finally, State of Alaska Department of Revenue increased its position in shares of DexCom by 32.3% during the second quarter. State of Alaska Department of Revenue now owns 10,410 shares of the medical device company’s stock worth $988,000 after buying an additional 2,540 shares during the period.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Story: Put Option

The Fly

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply